FDA Inspection 1068951 — Evonik Rexim (Nanning) Pharmaceutical Co. Ltd.
The FDA completed an inspection of Evonik Rexim (Nanning) Pharmaceutical Co. Ltd. on September 28, 2018 in Nanning. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- September 28, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Nanning (China)